Dr Palak Trivedi BSc (hons), MBBS, MRCP Gastro (UK), PhD

Palak Trivedi

Institute of Immunology and Immunotherapy
Associate Professor and Honorary Consultant Hepatologist
Clinical Research Director for Industry Engagement

Contact details

NIHR Birmingham BRC
Centre for Liver and Gastrointestinal Research
Institute of Immunology and Immunotherapy
ITM Building, Mindelsohn Way
University of Birmingham
B15 2TT

Dr. Trivedi is a Clinician Scientist in the National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre (BRC), based at the University of Birmingham. Dr. Trivedi is a Consultant Hepatologist who has devoted his clinical and research career to studying immune-mediated and chronic cholestatic liver disease, specifically primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC).

Palak is chief investigator for the UK-PSC consortium, and was elected chair of the British Association for Study of the Liver Special Interest Group (BASL SIG) for immune-mediated liver disease in 2018.


  • PhD in liver Immunology, University of Birmingham, 2015
  • Member of the Royal College of Physicians, London, 2008
  • MBBS, St. George’s Hospital Medical School, London, 2005
  • BSc (hons) in Medical Genetics, St. George’s Hospital Medical School, London, 2012


Palak completed his PhD in Liver Immunology in 2015, securing a competitively awarded Wellcome Trust Clinical Research Fellowship. During this time, his work on risk stratification in PBC was ranked the highest scoring clinical abstract at the EASL International Liver Congress.

Palak went on to receive the Investigator of the Year award in 2017 for work on gut-liver immunity in PSC, was recipient of the Andy Burroughs’ prize for best Hepatology research at the British Association for Study of the Liver (BASL), and won the Elwyn Elias prize for research into PSC and liver transplantation the same year. Palak is currently a mid-career researcher at the University of Birmingham, with 50% protected research time and the remainder dedicated to clinical practice.

Palak currently leads the PBC and PSC clinical research programme, with the overarching themes of work focussing on the role of gut-liver immunity, modelling the natural history of PBC and PSC, generating real-world clinical outcome data, and risk stratification pre- and post-transplantation.


  • Lead for the year 4 and 5 gastroenterology and hepatology MBChB programme

Postgraduate supervision

Post-doc supervision

  • Dr. Scott Davies
  • Dr. Hannah Crothers

MD/PhD supervision

  • Dr. Nadir Abbas
  • Dr. Sheeba Khan


  • Exercise intervention to attenuate symptoms in cholestasis
  • Epidemiology of primary sclerosing cholangitis
  • Risk stratification in chronic cholestatic liver disease
  • Characterising the natural history of PBC and PSC
  • Gut-liver immunity in the pathogenesis of autoimmune liver disease
  • Clinical trial design in rare disease
  • Immune-therapy induced liver injury
  • Exploring stability and function of regulatory T cells in human livers to develop and deliver immunotherapy for autoimmune hepatitis


Recent publications


UK-PBC audit group 2024, 'Critical shortfalls in the management of PBC: Results of a UK-wide, population-based evaluation of care delivery', JHEP Reports, vol. 6, no. 1, 100931. https://doi.org/10.1016/j.jhepr.2023.100931

the OCTAVE Collaborative Group, PITCH study, and the EASL supported COVID-Hep vaccine network, Murray, SM, Pose, E, Wittner, M, Londoño, MC, Schaub, G, Cook, J, Dimitriadis, S, Meacham, G, Irwin, S, Lim, Z, Duengelhoef, P, Sterneck, M, Lohse, AW, Perez, V, Trivedi, P, Bhandal, K, Mullish, BH, Manousou, P, Provine, NM, Avitabile, E, Carroll, M, Tipton, T, Healy, S, Burra, P, Klenerman, P, Dunachie, S, Kronsteiner, B, Maciola, AK, Pasqual, G, Hernandez-Gea, V, Garcia-Pagan, JC, Lampertico, P, Iavarone, M, Gines, P, Lütgehetmann, M, Schulze zur Wiesch, J, Russo, FP, Barnes, E & Marjot, T 2024, 'Immune responses and clinical outcomes after COVID-19 vaccination in patients with liver disease and liver transplant recipients', Journal of Hepatology, vol. 80, no. 1, pp. 109-123. https://doi.org/10.1016/j.jhep.2023.10.009

Trivedi, PJ, Arndtz, K, Abbas, N, Telford, A, Young, L, Banerjee, R, Eddowes, P, Jhaveri, KS & Hirschfield, GM 2024, 'Quantitative MRCP and metrics of bile duct disease over time in patients with primary sclerosing cholangitis: A prospective study', Alimentary Pharmacology & Therapeutics, pp. 1-10. https://doi.org/10.1111/apt.17944

Greenman, R, Segal-Salto, M, Barashi, N, Hay, O, Katav, A, Levi, O, Vaknin, I, Aricha, R, Aharoni, S, Snir, T, Mishalian, I, Olam, D, Amer, J, Salhab, A, Safadi, R, Maor, Y, Trivedi, P, Weston, CJ, Saffioti, F, Hall, A, Pinzani, M, Thorburn, D, Peled, A & Mor, A 2023, 'CCL24 regulates biliary inflammation and fibrosis in primary sclerosing cholangitis', JCI Insight, vol. 8, no. 12, e162270. https://doi.org/10.1172/jci.insight.162270

ESOT Guidelines Taskforce 2023, 'Liver Transplantation for Primary Sclerosing Cholangitis (PSC) With or Without Inflammatory Bowel Disease (IBD)—A European Society of Organ Transplantation (ESOT) Consensus Statement', Transplant international, vol. 36, 11729. https://doi.org/10.3389/ti.2023.11729

IAIHG and EASL DHILI Consortium 2023, 'Nomenclature, Diagnosis and Management of Drug-induced Autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report', Journal of Hepatology, vol. 79, no. 3, pp. 853-866. https://doi.org/10.1016/j.jhep.2023.04.033

Mayo, MJ, Vierling, JM, Bowlus, CL, Levy, C, Hirschfield, GM, Neff, GW, Galambos, MR, Gordon, SC, Borg, BB, Harrison, SA, Thuluvath, PJ, Goel, A, Shiffman, ML, Swain, MG, Jones, DEJ, Trivedi, P, Kremer, AE, Aspinall, RJ, Sheridan, DA, Dörffel, Y, Yang, K, Choi, YJ & McWherter, CA 2023, 'Open‐label, clinical trial extension: Two‐year safety and efficacy results of seladelpar in patients with primary biliary cholangitis', Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.17755

Abbas, N, Culver, EL, Thorburn, D, Halliday, N, Crothers, H, Dyson, JK, Phaw, A, Aspinall, R, Khakoo, SI, Kallis, Y, Smith, B, Patanwala, I, McCune, A, Chimakurthi, CR, Hegade, V, Orrell, M, Jones, R, Mells, G, Thain, C, Thain, R-M, Jones, D, Hirschfield, G & Trivedi, PJ 2023, 'UK-Wide Multicenter Evaluation of Second-line Therapies in Primary Biliary Cholangitis', Clinical Gastroenterology and Hepatology, vol. 21, no. 6, pp. 1561-1570.e13. https://doi.org/10.1016/j.cgh.2022.07.038

UK-PBC audit collaborators 2022, 'The national audit of primary biliary cholangitis (PBC) in the United Kingdom: defining the audit dataset and data collection system', Cureus, vol. 14, no. 6, e25609. https://doi.org/10.7759/cureus.25609

Trivedi, PJ, Crothers, H, Mytton, J, Bosch, S, Iqbal, T, Ferguson, J & Hirschfield, GM 2020, 'Effects of primary sclerosing cholangitis on risks of cancer and death in people with inflammatory bowel diseases, based on sex, race, and age', Gastroenterology, vol. 159, no. 3, pp. 915-928. https://doi.org/10.1053/j.gastro.2020.05.049

International Primary Sclerosing Cholangitis Study Group (IPSCSG) 2020, 'Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases', Clinical Gastroenterology and Hepatology, vol. 18, no. 1, pp. 179-187.e6. https://doi.org/10.1016/j.cgh.2019.05.013

Global PBC Study Group 2020, 'Goals of treatment for improved survival in primary biliary cholangitis: treatment target should be bilirubin within the normal range and normalization of alkaline phosphatase', The American Journal of Gastroenterology, vol. 115, no. 7, pp. 1066-1074. https://doi.org/10.14309/ajg.0000000000000557


Freer, A, Williams, F, Durman, S, Hayden, J, Armstrong, M & Trivedi, P 2022, 'Home-based exercise in patients with refractory fatigue associated primary biliary cholangitis: final results from the EXerCise Intervention in cholesTatic LivEr Disease (EXCITED) clinical trial', Journal of Hepatology, vol. 77, no. Supplement 1, pp. S334-S335. https://doi.org/10.1016/S0168-8278(22)01032-7

Review article

Trivedi, PJ, Hirschfield, GM, Adams, DH & Vierling, JM 2024, 'Immunopathogenesis of Primary Biliary Cholangitis, Primary Sclerosing Cholangitis and Autoimmune Hepatitis: Themes and Concepts', Gastroenterology, vol. 166, no. 6, pp. 995-1019. https://doi.org/10.1053/j.gastro.2024.01.049

Ricciuto, A, Kamath, BM, Hirschfield, GM & Trivedi, PJ 2023, 'Primary sclerosing cholangitis and overlap features of autoimmune hepatitis: A coming of age or an age-ist problem?', Journal of Hepatology, vol. 79, no. 2, pp. 567-575. https://doi.org/10.1016/j.jhep.2023.02.030

View all publications in research portal